Novo Nordisk CEO tells investors to expect weight-loss drug pricing to go down before it comes back up

Recently-appointed CEO Mike Doustdar has repeatedly reset expectations since his arrival. Pricing and regulatory pressure is fierce and pessimistic revenue guidance has seen the stock clobbered 17% in Copenhagen.